Volume 74, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


This randomized, open-label study compared a three-day, six-dose regimen of artemether-lumefantrine with a five-day, 19-dose regimen of quinine-doxycycline for the treatment of malaria in the western Amazon region of Brazil. All patients remained hospitalized during their treatment and the study assessments were scheduled daily from the start of treatment (day 0) through day 6. By day 3, the percentage of infected patients was 0% in the artemether-lumefantrine group and 48.8% in the quinine-doxycycline group. Median parasite clearance time was significantly shorter in the artemether-lumefantrine group (two days) compared with the quinine-doxycycline group (three days) ( < 0.0001). Two patients in the quinine-doxycycline group left the study early because of treatment ineffectiveness or adverse event. Adverse events were reported by 91.5% of the study participants, most of which were mild in severity and/or not considered related to study treatment. Artemether-lumefantrine was shown to be an efficacious, safe, and convenient treatment for malaria in a highly drug-resistant region of South America.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Cortese JF, Caraballo A, Contreras CE, Plowe CV, 2002. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis 186 : 999–1006. [Google Scholar]
  2. PAHO, 2003. Report on the Status of Malaria Programs in the Americas (Based on 2002 Data). Available from http://www.who.int/malaria/cmc_upload/0/000/016/856/cd44_inf3-e.pdf. Accessed March 21, 2005.
  3. USAID, 2002. Drug-Resistant Malaria: Amazon Malaria Initiative. Available from http://www.usaid.gov/pop_health/id/malaria/techareas/amazon_resistant.html. Accessed July 17, 2003.
  4. Petralanda I, 1995. Quality of antimalarial drugs and resistance to Plasmodium vivax in Amazonian region. Lancet 345 : 1433. [Google Scholar]
  5. WHO/TDR, 2003. Roll Back Malaria Update: Rolling Back in the Americas. Available from http://www.who.int/tdr/publications/tdrnews/news61/rbm.htm. Accessed July 17, 2003.
  6. Marquino W, MacArthur JR, Barat LM, Oblitas FE, Arrunategui M, Garavito G, Chafloque ML, Pardave B, Gutierrez S, Arrospide N, Carrillo C, Cabezas C, Ruebush TK 2nd, 2003. Efficacy of chloroquine, sulfadoxine-pyrimethamine, and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria on the north coast of Peru. Am J Trop Med Hyg 68 : 120–123. [Google Scholar]
  7. Duarte EC, Fontes CJ, Gyorkos TW, Abrahamowicz M, 1996. Randomized controlled trial of artesunate plus tetracycline versus standard treatment (quinine plus tetracycline) for uncomplicated Plasmodium falciparum malaria in Brazil. Am J Trop Med Hyg 54 : 197–202. [Google Scholar]
  8. Leal O, Leal EA, Borges Junior FR, Paez ML, Teodosio S, Tavares-Neto J, 2003. Clinical-parasitological response to treatment with quinine associated to doxycycline in uncomplicated falciparum malaria. Rev Soc Bras Med Trop 36 : 751–754. [Google Scholar]
  9. von Seidlein L, Bojang K, Jones P, Jaffar S, Pinder M, Obaro S, Doherty T, Haywood M, Snounou G, Gemperli B, Gathmann I, Royce C, McAdam K, Greenwood B, 1998. A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children. Am J Trop Med Hyg 58 : 638–644. [Google Scholar]
  10. van Agtmael M, Bouchaud O, Malvy D, Delmont J, Danis M, Barette S, Gras C, Bernard J, Touze JE, Gathmann I, Mull R, 1999. The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the tropics to The Netherlands and France. Int J Antimicrob Agents 12 : 159–169. [Google Scholar]
  11. Vugt MV, Wilairatana P, Gemperli B, Gathmann I, Phaipun L, Brockman A, Luxemburger C, White NJ, Nosten F, Looareesuwan S, 1999. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 60 : 936–942. [Google Scholar]
  12. Lefevre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Sila-chamroon U, Gathmann I, Mull R, Bakshi R, 2001. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 64 : 247–256. [Google Scholar]
  13. White NJ, van Vugt M, Ezzet F, 1999. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 37 : 105–125. [Google Scholar]
  14. Olliaro P, 2001. Mode of action and mechanisms of resistance for antimalarial drugs. Pharmacol Ther 89 : 207–219. [Google Scholar]
  15. Hien TT, VinhChau NV, Vinh NN, Hung NT, Phung MQ, Toan LM, Mai PP, Dung NT, HoaiTam DT, Arnold K, 1997. Management of multiple drug-resistant malaria in Viet Nam. Ann Acad Med Singapore 26: 659–663. [Google Scholar]
  16. van Vugt M, Brockman A, Gemperli B, Luxemburger C, Gathmann I, Royce C, Slight T, Looareesuwan S, White NJ, Nosten F, 1998. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother 42 : 135–139. [Google Scholar]
  17. van Vugt M, Ezzet F, Nosten F, Gathmann I, Wilairatana P, Looareesuwan S, White NJ, 1999. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg 61 : 964–967. [Google Scholar]
  18. Hatz C, Abdulla S, Mull R, Schellenberg D, Gathmann I, Kibatala P, Beck HP, Tanner M, Royce C, 1998. Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1–5 years. Trop Med Int Health 3 : 498–504. [Google Scholar]
  19. Bakshi R, Hermeling-Fritz I, Gathmann I, Alteri E, 2000. An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. Trans R Soc Trop Med Hyg 94 : 419–424. [Google Scholar]
  20. Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, White NJ, 1993. Cardiac effects of antimalarial treatment with halofantrine. Lancet 341 : 1054–1056. [Google Scholar]
  21. Bindschedler M, Lefevre G, Ezzet F, Schaeffer N, Meyer I, Thomsen MS, 2000. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. Eur J Clin Pharmacol 56 : 375–381. [Google Scholar]
  22. Guerin PJ, Olliaro P, Nosten F, Druilhe P, Laxminarayan R, Binka F, Kilama WL, Ford N, White NJ, 2002. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis 2 : 564–573. [Google Scholar]
  23. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, White NJ, 1996. Effects of artemisinin derivatives on malaria transmissibility. Lancet 347 : 1654–1658. [Google Scholar]
  24. Looareesuwan S, Wilairatana P, Chokejindachai W, Chalermrut K, Wernsdorfer W, Gemperli B, Gathmann I, Royce C, 1999. A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 60 : 238–243. [Google Scholar]

Data & Media loading...

  • Received : 24 Jun 2004
  • Accepted : 19 May 2005

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error